Left atrial appendage closure fails noninferiority test versus medical therapy in high-risk AF patients
A multicenter randomized controlled trial in Germany compared catheter-based left atrial appendage closure to physician-directed best medical care (including direct oral anticoagulants when eligible) in 912 adult patients with atrial fibrillation at high risk for both stroke and bleeding. The primary outcome was a composite of stroke (ischemic or hemorrhagic), systemic embolism, major bleeding, or cardiovascular or unexplained death, assessed over a median follow-up of 3 years.
For the primary composite endpoint, 155 events occurred in the device group (446 patients) compared to 127 events in the medical-therapy group (442 patients). The difference in restricted mean survival time was -0.36 years (95% CI: -0.70 to -0.01), and the trial did not meet its pre-specified noninferiority margin (hazard ratio of 1.3), with a P-value of 0.44 for noninferiority. The incidence of serious adverse events was higher in the device group (82.5%) than in the medical-therapy group (77.4%).
Key limitations include the lack of reported data on specific adverse events, discontinuations, and tolerability. The trial was funded by the German Center for Cardiovascular Research. The findings indicate that, in this high-risk population with a mean CHADS-VASc score of 5.2 and HAS-BLED score of 3.0, left atrial appendage closure was not shown to be noninferior to optimized medical therapy for the composite clinical endpoint over 3 years.